Shou-Sen Huang1, Chung-Hsin Tsai2, Chi-Yu Kuo2, Ying-Syuan Li2, Shih-Ping Cheng3,4,5. 1. Department of Surgery, Taitung MacKay Memorial Hospital, Taitung, Taiwan. 2. Department of Surgery, MacKay Memorial Hospital and MacKay Medical College, Taipei, Taiwan. 3. Department of Surgery, MacKay Memorial Hospital and MacKay Medical College, Taipei, Taiwan. surg.mmh@gmail.com. 4. Institute of Biomedical Sciences, MacKay Medical College, New Taipei City, Taiwan. surg.mmh@gmail.com. 5. Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. surg.mmh@gmail.com.
Abstract
PURPOSE: ATP-citrate lyase (ACLY) is a critical enzyme at the intersection of glucose and lipid metabolism. ACLY is often upregulated or activated in cancer cells to accelerate lipid synthesis and promote tumor progression. In this study, we aimed to explore the possibility of utilizing ACLY inhibition as a new strategy in the treatment of thyroid cancer. METHODS: Bioinformatics analysis of the public datasets was performed. Thyroid cancer cells were treated with two different ACLY inhibitors, SB-204990 and NDI-091143. RESULTS: Bioinformatics analysis revealed that ACLY expression was increased in anaplastic thyroid cancer. In thyroid cancer cell lines FTC-133 and 8505C, ACLY inhibitors suppressed monolayer cell growth and clonogenic ability in a dose-dependent and time-dependent manner. Flow cytometry analysis showed that ACLY inhibitors increased the proportion of sub-G1 cells in the cell cycle and the number of annexin V-positive cells. Immunoblotting confirmed caspase-3 activation and PARP1 cleavage following treatment with ACLY inhibitors. Compromised cell viability could be partially rescued by co-treatment with the pan-caspase inhibitor Z-VAD-FMK. Additionally, we showed that ACLY inhibitors impeded three-dimensional growth and cell invasion in thyroid cancer cells. Isobolograms and combination index analysis indicated that ACLY inhibitors synergistically potentiated the cytotoxicity rendered by sorafenib. CONCLUSIONS: Targeting ACLY holds the potential for being a novel therapeutic strategy for thyroid cancer.
PURPOSE: ATP-citrate lyase (ACLY) is a critical enzyme at the intersection of glucose and lipid metabolism. ACLY is often upregulated or activated in cancer cells to accelerate lipid synthesis and promote tumor progression. In this study, we aimed to explore the possibility of utilizing ACLY inhibition as a new strategy in the treatment of thyroid cancer. METHODS: Bioinformatics analysis of the public datasets was performed. Thyroid cancer cells were treated with two different ACLY inhibitors, SB-204990 and NDI-091143. RESULTS: Bioinformatics analysis revealed that ACLY expression was increased in anaplastic thyroid cancer. In thyroid cancer cell lines FTC-133 and 8505C, ACLY inhibitors suppressed monolayer cell growth and clonogenic ability in a dose-dependent and time-dependent manner. Flow cytometry analysis showed that ACLY inhibitors increased the proportion of sub-G1 cells in the cell cycle and the number of annexin V-positive cells. Immunoblotting confirmed caspase-3 activation and PARP1 cleavage following treatment with ACLY inhibitors. Compromised cell viability could be partially rescued by co-treatment with the pan-caspase inhibitor Z-VAD-FMK. Additionally, we showed that ACLY inhibitors impeded three-dimensional growth and cell invasion in thyroid cancer cells. Isobolograms and combination index analysis indicated that ACLY inhibitors synergistically potentiated the cytotoxicity rendered by sorafenib. CONCLUSIONS: Targeting ACLY holds the potential for being a novel therapeutic strategy for thyroid cancer.
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Giuliana Salvatore; Tito Claudio Nappi; Paolo Salerno; Yuan Jiang; Corrado Garbi; Clara Ugolini; Paolo Miccoli; Fulvio Basolo; Maria Domenica Castellone; Anna Maria Cirafici; Rosa Marina Melillo; Alfredo Fusco; Michael L Bittner; Massimo Santoro Journal: Cancer Res Date: 2007-11-01 Impact factor: 12.701
Authors: Philippe Icard; Zherui Wu; Ludovic Fournel; Antoine Coquerel; Hubert Lincet; Marco Alifano Journal: Cancer Lett Date: 2019-12-09 Impact factor: 8.679
Authors: Koen H G Verschueren; Clement Blanchet; Jan Felix; Ann Dansercoer; Dirk De Vos; Yehudi Bloch; Jozef Van Beeumen; Dmitri Svergun; Irina Gutsche; Savvas N Savvides; Kenneth Verstraete Journal: Nature Date: 2019-04-03 Impact factor: 49.962